查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870155

Gabapentin市场依给药途径、製剂、剂型、通路、最终用户和适应症划分－2025-2032年全球预测

Gabapentin Market by Route Of Administration, Formulation, Dosage Form, Distribution Channel, End User, Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，Gabapentin市场规模将成长至 33 亿美元，复合年增长率为 4.50%。

关键市场统计数据
基准年 2024 23.2亿美元
预计年份：2025年 24.3亿美元
预测年份 2032 33亿美元
复合年增长率 (%) 4.50%

全面介绍Gabapentin在神经病学和疼痛管理领域不断发展的临床应用、商业性趋势和策略定位

Gabapentin在现代神经病学和疼痛管理中发挥核心作用，可用于治疗多种慢性及急性疾病。最初作为抗惊厥药物引入临床，如今其治疗范围已扩展至神经病变疼痛综合症和运动障碍，使其成为全球常用药物之一。临床应用模式反映了疗效、耐受性和成本等因素的综合考量，并推动临床医师在製剂选择、剂量策略和给药途径等方面不断改进。

深入分析临床偏好、製造现代化、监管加强和通路演变如何重塑Gabapentin的竞争格局。

临床实务、生产技术和监管政策等多种因素的共同作用，正在推动Gabapentin市场格局的变革时期。在临床上，个人化治疗方案的选择变得日益重要。处方医师在急性期治疗中越来越重视口服和肠外给药途径的权衡，而依从性和耐受性则成为长期用药选择的重要标准。同时，製剂创新（尤其是缓释片和新型胶囊基质）正在解决依从性问题，并改善稳态药物动力学，这些都对处方模式和医疗保险支付方的评估产生了影响。

深入检验2025年美国关税对Gabapentin供应链、采购经济及战略采购因应措施的累积影响

2025年的政策干预，特别是对医药中间体和成品製剂征收关税，正累积改变美国Gabapentin的供应链经济格局。对某些活性原料药（API）和进口商品征收的关税措施增加了部分成品和原材料的到岸成本，促使企业重新评估采购基础。为此，生产商和经销商正在加快多元化步伐，在免税地区寻找替代供应商，并评估国内API生产，以降低进口关税和运输成本波动带来的风险。

全面的細項分析揭示了给药途径、製剂类型、剂型、分销管道、终端用户环境和临床适应症如何影响需求模式。

针对不同细分维度的详细分析揭示了需求驱动因素和商业性影响的差异。根据给药途径，口服Gabapentin因其在门诊治疗中的便利性和良好的依从性，仍然是慢性病管理的主要治疗方法；而注射剂型则更适用于急性住院治疗以及需要快速调整剂量的情况。口服和注射剂型之间的转换具有重要的临床意义，尤其是在医院环境中，药物选择会影响给药通讯协定和住院时间。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大取得专利的缓释性Gabapentin製剂在神经病变疼痛管理的应用
  • 非专利药生产商之间日益激烈的价格竞争正在影响市场利润率。
  • 新的临床证据支持Gabapentin用于治疗纤维肌痛及仿单标示外疾病。
  • 加强对Gabapentin处方行为的监管，以防止滥用
  • 整合数位化依从性工具以优化慢性疼痛患者的Gabapentin治疗效果
  • 製药公司和生技公司进行策略合作，开发Gabapentin联合治疗以提高疗效
  • 供应链创新缩短了前置作业时间，并确保了非专利处方药Gabapentin的全球稳定供应。
  • 利用基因谱分析的个人化医疗方法优化Gabapentin喷丁给药方案

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Gabapentin市场依给药途径划分

  • 口服
  • 肠外给药

第九章Gabapentin市场按剂型划分

  • 品牌产品
  • 学名药

第十章Gabapentin市场按剂型划分

  • 胶囊
    • 硬明胶胶囊
    • 软胶囊
  • 口服液
  • 药片
    • 缓释性
    • 立即发布

第十一章Gabapentin市场分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第十二章Gabapentin市场（依最终用户划分）

  • 诊所
  • 居家医疗
  • 医院

第十三章Gabapentin市场依适应症划分

  • 癫痫
  • 神经病变疼痛
    • 糖尿病神经病变
    • 带状疱疹后遗症神经痛
  • 不宁腿

第十四章Gabapentin市场区域划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章Gabapentin市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国Gabapentin丁市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Apotex Inc.
    • Sandoz International GmbH
    • Sun Pharmaceutical Industries Ltd.
    • Cipla Ltd.
    • Zydus Lifesciences Ltd.
    • Torrent Pharmaceuticals Ltd.
    • Alembic Pharmaceuticals Ltd.
    • Lupin Ltd.
Product Code: MRR-3204321AF706

The Gabapentin Market is projected to grow by USD 3.30 billion at a CAGR of 4.50% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.32 billion
Estimated Year [2025] USD 2.43 billion
Forecast Year [2032] USD 3.30 billion
CAGR (%) 4.50%

Comprehensive introduction to gabapentin's evolving clinical applications, commercial dynamics, and strategic positioning across neurology and pain management landscapes

Gabapentin occupies a central role in contemporary neurology and pain management practice, serving multiple indications across chronic and acute care settings. Initially introduced as an anticonvulsant, its therapeutic profile now extends into neuropathic pain syndromes and movement disorders, making it a staple in formularies worldwide. Clinical adoption patterns reflect an intersection of efficacy, tolerability, and cost considerations, driving continuous evolution in how clinicians select formulations, dosing strategies, and routes of administration.

Commercially, gabapentin's trajectory mirrors a broader maturation of the small-molecule analgesic and antiepileptic segments: branded originator products gave way to widespread generic manufacturing, prompting price competition, variations in supply-chain resilience, and a proliferation of dosage forms designed to optimize adherence. At the same time, regulatory scrutiny, patent expirations and reformulation efforts aimed at improving pharmacokinetics have shaped the development pipeline. Taken together, these clinical and commercial forces create a dynamic environment that requires stakeholders to balance therapeutic differentiation against cost-efficiency and regulatory compliance.

This executive synthesis distills the salient drivers of clinical use and commercial performance, highlighting the implications of route-of-administration choices, formulation strategies, dosage form innovations, distribution channel preferences, and indication-specific demand characteristics. It frames the emerging policy and trade developments that are reshaping supply economics, while offering targeted insights for manufacturers, wholesalers, hospital procurement teams, and specialty pharmacies seeking to optimize positioning amid shifting market and regulatory pressures.

Detailed analysis of how clinical preferences, manufacturing modernization, regulatory tightening, and channel evolution are reshaping gabapentin's competitive environment

The gabapentin landscape is undergoing transformative shifts driven by converging forces in clinical practice, manufacturing technology, and regulatory policy. Clinically, there is growing emphasis on individualized therapy selection: prescribers increasingly weigh route-of-administration trade-offs between oral regimens and parenteral approaches for acute interventions, with adherence and tolerability shaping long-term preference. Concurrently, formulation innovation-particularly in extended-release tablets and novel capsule matrices-seeks to address compliance gaps and improve steady-state pharmacokinetics, which in turn affects prescribing patterns and payer evaluations.

Manufacturing and supply-chain modernization have accelerated, with contract manufacturers and large generics players investing in capacity upgrades and quality systems to mitigate shortages and quality-related recalls. This has prompted a reconfiguration of sourcing strategies for active pharmaceutical ingredients and finished dosage forms, increasing collaboration between raw material suppliers, API producers, and finished-dose manufacturers. Regulatory oversight has tightened in parallel, prompting enhanced transparency around manufacturing sites and quality controls; this leads to more rigorous supplier qualification practices and higher upfront compliance costs for new entrants.

Market access and distribution models have also shifted. The rise of online pharmacies as a complementary channel to hospital and retail pharmacies has altered patient acquisition and refill dynamics, necessitating integrated channel strategies that bridge digital engagement with traditional procurement flows. In addition, payer scrutiny and utilization management for neurologic and pain indications are influencing formulary placement and prescribing incentives, encouraging manufacturers to demonstrate value through real-world evidence, patient support programs, and targeted clinical differentiation. These transformative shifts underscore the imperative for all stakeholders to adopt agile operations, invest in quality and differentiation, and align clinical evidence generation with commercial pathways.

In-depth examination of the cumulative effects of 2025 United States tariff measures on gabapentin supply chains, procurement economics, and strategic sourcing responses

Policy interventions in 2025, particularly the introduction of tariffs affecting pharmaceutical intermediates and finished formulations, are cumulatively altering supply-chain economics for gabapentin within the United States. Tariff measures on selected APIs and import categories have raised landed costs for some finished products and raw materials, incentivizing a reassessment of sourcing footprints. In response, manufacturers and distributors have accelerated diversification efforts, seeking alternative suppliers in tariff-exempt jurisdictions and evaluating domestic API production to reduce exposure to import levies and transportation volatility.

These tariff-induced cost pressures have a particularly pronounced effect on lower-margin generic gabapentin products, where distribution and procurement teams must balance price sensitivity with supply continuity. Higher manufacturing overheads and reallocated logistics expenses may prompt tendering cycles to favor suppliers with vertically integrated operations or those holding strategic inventory buffers. At the same time, clinical delivery for indications that require specific dosage forms-such as extended-release tablets or parenteral presentations-may face different levels of impact depending on where the manufacturing steps occur and whether those components fall under tariff schedules.

Regulatory responses and trade policy mitigations are shaping the operational playbook. Firms are engaging more actively with trade advisors to pursue classification reviews, rulings, and temporary exemptions where available, while supply-chain teams are implementing dual-sourcing and nearshoring strategies to reduce tariff exposure. Payers and procurement entities are also responding by re-evaluating contract terms, introducing longer lead-time clauses, and stressing continuity-of-supply clauses to preserve patient care pathways. Taken together, these measures create a more complex procurement environment where cost management must be balanced against clinical risk and regulatory compliance.

Comprehensive segmentation analysis revealing how administration routes, formulation types, dosage forms, distribution channels, end-user settings, and clinical indications sculpt demand patterns

A granular view across segmentation dimensions reveals differentiated demand drivers and commercial implications. Based on route of administration, oral gabapentin remains the dominant modality for chronic management due to outpatient convenience and adherence considerations, while parenteral options are positioned for acute inpatient settings or situations requiring rapid titration. Transition pathways between oral and parenteral forms are clinically meaningful, particularly in hospital settings where formulary choices influence dosing protocols and length of stay.

Based on formulation, branded offerings continue to leverage perception of consistent supply and patient support services, whereas generic formulations drive volume-based procurement through cost advantages. Manufacturers and payers negotiate around the trade-offs between price and perceived product reliability, with branded suppliers often investing in services and patient adherence programs to maintain differentiated value propositions. Based on dosage form, capsules, oral solutions, and tablets each present unique market dynamics: capsules-further segmented into hard gelatin and soft gelatin types-offer formulation flexibility and patient acceptability, oral solutions support pediatric and dysphagia populations, and tablets-divided into extended-release and immediate-release variants-address adherence and pharmacokinetic optimization needs. These dosage-form distinctions inform manufacturing complexity, packaging choices, and channel stocking decisions.

Based on distribution channel, hospital pharmacies prioritize formulary equivalence and supply continuity, online pharmacies emphasize convenience, refill management, and direct-to-patient services, while retail pharmacies balance walk-in demand with prescription volume and local prescriber relationships. Each channel requires tailored logistics, inventory strategies, and patient education approaches. Based on end user, clinics, home care providers, and hospitals display divergent purchasing cycles and clinical protocols; clinics and hospitals often engage in tendered purchasing with volume commitments and payer negotiations, while home care channels prioritize ease of administration and patient support. Finally, based on indication, epilepsy, neuropathic pain, and restless leg syndrome create distinct utilization patterns: neuropathic pain subdivides into diabetic neuropathy and postherpetic neuralgia, each with unique clinical pathways and comorbidity considerations that affect dosing strategies, real-world outcomes measurement, and payer positioning. These segmentation insights collectively inform product development priorities, channel strategies, and clinical engagement plans for manufacturers and distributors alike.

Strategic regional intelligence that contrasts regulatory regimes, procurement models, and distribution realities across the Americas, Europe Middle East & Africa, and Asia-Pacific territories

Regional dynamics shape both clinical practice and commercial strategy for gabapentin, with the Americas, Europe, Middle East & Africa, and Asia-Pacific each presenting distinct regulatory, payer, and manufacturing considerations. In the Americas, strong outpatient care infrastructure and mature retail and online pharmacy channels support high-volume generic distribution, while hospital procurement emphasizes continuity and therapeutic interchange protocols. Pricing pressures coexist with advanced pharmacovigilance systems, prompting manufacturers to align post-marketing surveillance and patient-support initiatives with payer requirements.

In Europe, Middle East & Africa the regulatory landscape varies widely across sub-regions: European markets are characterized by rigorous approval pathways, centralized pharmacovigilance, and differentiated reimbursement mechanisms that favor evidence of therapeutic benefit and cost-effectiveness. The Middle East exhibits demand driven by expanding hospital networks and increasing adoption of standardized neurology protocols, whereas parts of Africa face access constraints and supply reliability challenges that elevate the importance of robust distribution partnerships and quality-assured sourcing. Cross-border regulatory harmonization efforts and regional procurement mechanisms influence how manufacturers design market-entry and supply strategies.

In the Asia-Pacific region, diverse market sophistication levels create both high-growth opportunities and operational complexity. Developed markets within the region show rapid uptake of digital pharmacy models and value-based procurement, while emerging markets balance affordability considerations with expanding clinical capacity. The region is also a key node for global manufacturing and API supply, with implications for tariffs, trade policy, and contingency planning. Collectively, these regional insights underline the need for differentiated market strategies that account for regulatory nuance, procurement models, and local clinical practice patterns.

Insightful evaluation of how manufacturing scale, regulatory compliance, formulation differentiation, and strategic partnerships drive competitive advantage among gabapentin suppliers

Competitive dynamics among companies engaged with gabapentin center on scale economics in manufacturing, portfolio breadth across dosage forms, and the ability to deliver dependable supply under tightening regulatory scrutiny. Originator brands historically established clinical recognition and patient-support frameworks, which many generic manufacturers seek to replicate through service offerings and enhanced packaging. Large generics firms have leveraged manufacturing scale to compete on price while investing selectively in differentiated formulations such as extended-release tablets and specialty capsules to capture niche segments.

Strategic partnerships and contract manufacturing relationships have proliferated as firms optimize capacity utilization and de-risk supply. Companies with integrated API capabilities demonstrate resilience when trade disruptions or tariff pressures emerge, while those reliant on third-party suppliers face higher negotiation complexity and potential exposure. In addition, firms investing in quality management systems and regulatory compliance can convert reliability into commercial advantage, particularly with hospital and institutional buyers where tender outcomes favor proven suppliers.

On the innovation front, companies pursuing formulation improvements, pediatric-friendly presentations, and adherence-enhancing packaging aim to distinguish their offerings in congested generic markets. Corporate strategies also include geographic diversification of manufacturing and sales footprints, mergers and acquisitions to consolidate capabilities, and collaborations with specialty distributors and digital health platforms to expand access and patient engagement. These company-level behaviors collectively define a competitive landscape where operational excellence, regulatory readiness, and selective differentiation determine long-term positioning.

Actionable strategic recommendations for manufacturers, distributors, and payers to enhance supply resilience, clinical differentiation, and channel integration in gabapentin portfolios

Industry leaders should adopt a multi-faceted strategy that balances operational resilience, clinical differentiation, and channel optimization to maintain competitiveness in the gabapentin space. Strengthening supplier qualification programs and diversifying API sourcing will reduce exposure to trade-induced cost shocks and capacity constraints, while investments in domestic or nearshore manufacturing capacity can serve as a hedge against import tariffs and logistical disruptions. Coupled with inventory optimization and demand-forecasting enhancements, these operational moves will protect continuity of patient care and institutional contracts.

On the commercial side, prioritizing dosage-form differentiation-such as extended-release tablets and patient-friendly oral solutions-can create pockets of value that extend beyond price competition. Demonstrating real-world outcomes and adherence benefits through targeted evidence generation will enhance formulary positioning and payer conversations. In parallel, building robust channel strategies that integrate hospital pharmacy relationships, retail pharmacy partnerships, and online pharmacy capabilities will capture diverse patient touchpoints and strengthen refill retention. Digital patient support, adherence tools, and targeted clinician education programs can further unlock value by reducing discontinuation rates and improving long-term use.

Finally, proactive engagement with policymakers and trade advisors to navigate tariff classifications and seek exemptions where appropriate can mitigate near-term cost impacts. Executing strategic collaborations with contract manufacturers and quality-focused partners will accelerate capacity scaling while preserving compliance. By combining operational hedging, evidence-driven differentiation, and integrated channel management, industry leaders can secure sustainable advantage in a market shaped by regulatory change and evolving clinical practice.

Transparent mixed-methods research approach integrating primary expert interviews, regulatory and trade data reviews, and scenario analysis to produce robust strategic insights

The research underpinning this executive synthesis employed a mixed-methods approach designed to triangulate industry intelligence across primary and secondary sources. Primary research included structured interviews with clinical experts, hospital pharmacy directors, supply-chain managers, and distribution executives to capture real-world procurement practices, clinical preferences across indications, and channel-specific operational constraints. These interviews provided qualitative depth on formulary decision drivers, adherence challenges, and the practical implications of sourcing shifts under tariff pressures.

Secondary research encompassed review of regulatory filings, product labeling, and publicly available pharmacovigilance data to verify clinical indications, dosing paradigms, and safety profiles. Trade and customs datasets informed analysis of import/export flows and tariff exposure, while patent and regulatory-action databases were consulted to map intellectual property landscapes and approval histories where relevant. Financial disclosures and investor presentations from publicly listed manufacturers offered context on capacity expansion, capital allocation, and strategic partnerships.

Analytic techniques combined thematic coding of interview transcripts with cross-sectional comparison of regulatory and trade datasets to identify systemic patterns. Scenario analysis explored plausible responses to tariff shocks and supply disruptions, while sensitivity checks ensured robustness of strategic inferences. Throughout, the methodology prioritized transparency and reproducibility by documenting source provenance, interview protocols, and assumptions used in qualitative synthesis. This approach produced a grounded, multi-dimensional view of market dynamics while ensuring that practical recommendations remained closely tied to observable industry behaviors and verified regulatory information.

Concluding synthesis that distills operational imperatives, clinical differentiation levers, and regional nuances essential for sustaining gabapentin access and commercial resilience

In conclusion, gabapentin remains a therapeutically vital and commercially complex product class that sits at the intersection of clinical need, manufacturing realities, and policy developments. The prevailing trends-growing emphasis on adherence-focused formulations, heightened regulatory expectations for manufacturing quality, and trade-policy volatility-collectively require manufacturers and distributors to adopt resilient, evidence-informed strategies. Those able to secure reliable supply chains, demonstrate clinical value beyond price, and execute multi-channel distribution plans will find the preconditions for sustainable advantage.

The interplay between route of administration choices, formulation differentiation, dosage form innovation, and distribution channel selection creates multiple levers for strategic action. Regional differences in regulatory and procurement models further underscore the importance of localized strategies rather than one-size-fits-all approaches. Firms that invest in quality systems, diversify sourcing, and prioritize real-world evidence generation will be best positioned to navigate tariff-related cost pressures and shifting payer expectations.

Ultimately, the next phase of competition in the gabapentin environment will favor entities that combine operational excellence with targeted clinical and commercial differentiation. Proactive planning today-grounded in the segmentation and regional insights outlined here-will be instrumental in protecting patient access and securing long-term commercial resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of patented extended-release gabapentin formulations in neuropathic pain management
  • 5.2. Escalating price competition among generic gabapentin manufacturers affecting market margins
  • 5.3. Emerging clinical evidence supporting gabapentin use in treating fibromyalgia and off-label conditions
  • 5.4. Regulatory agencies intensifying monitoring of gabapentin prescribing practices to curb misuse
  • 5.5. Integration of digital adherence tools to optimize gabapentin therapy outcomes in chronic pain patients
  • 5.6. Strategic partnerships between pharma and biotech firms to develop gabapentin combination therapies with improved efficacy
  • 5.7. Supply chain innovations reducing lead times and ensuring consistent availability of gabapentin generics globally
  • 5.8. Personalized medicine approaches leveraging genetic profiling to tailor gabapentin dosing regimens

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gabapentin Market, by Route Of Administration

  • 8.1. Oral
  • 8.2. Parenteral

9. Gabapentin Market, by Formulation

  • 9.1. Branded
  • 9.2. Generic

10. Gabapentin Market, by Dosage Form

  • 10.1. Capsules
    • 10.1.1. Hard Gelatin
    • 10.1.2. Soft Gelatin
  • 10.2. Oral Solution
  • 10.3. Tablets
    • 10.3.1. Extended Release
    • 10.3.2. Immediate Release

11. Gabapentin Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Gabapentin Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Gabapentin Market, by Indication

  • 13.1. Epilepsy
  • 13.2. Neuropathic Pain
    • 13.2.1. Diabetic Neuropathy
    • 13.2.2. Postherpetic Neuralgia
  • 13.3. Restless Leg Syndrome

14. Gabapentin Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Gabapentin Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gabapentin Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Teva Pharmaceutical Industries Ltd.
    • 17.3.2. Viatris Inc.
    • 17.3.3. Apotex Inc.
    • 17.3.4. Sandoz International GmbH
    • 17.3.5. Sun Pharmaceutical Industries Ltd.
    • 17.3.6. Cipla Ltd.
    • 17.3.7. Zydus Lifesciences Ltd.
    • 17.3.8. Torrent Pharmaceuticals Ltd.
    • 17.3.9. Alembic Pharmaceuticals Ltd.
    • 17.3.10. Lupin Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GABAPENTIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS GABAPENTIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GABAPENTIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GABAPENTIN MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS GABAPENTIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS GABAPENTIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 328. ASEAN GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 329. ASEAN GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 330. ASEAN GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 331. ASEAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. ASEAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. ASEAN GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. ASEAN GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. ASEAN GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 336. ASEAN GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 339. GCC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 340. GCC GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 341. GCC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 342. GCC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 343. GCC GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 344. GCC GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 345. GCC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 346. GCC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 347. GCC GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 348. GCC GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 349. GCC GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 350. GCC GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 351. GCC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. GCC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 353. GCC GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 354. GCC GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 355. GCC GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 356. GCC GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 357. GCC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 358. GCC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 359. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 360. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 361. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 362. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 363. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 364. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 365. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 366. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 367. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 368. EUROPEA